Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies
Dirk M. Nettelbeck, Mathias F. Leber, Jennifer Altomonte, et al.
Viruses (2021) Vol. 13, Iss. 8, pp. 1420-1420
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy
Simona Ruxandra Volovăț, Dragoş Viorel Scripcariu, Ingrid-Andrada Vasilache, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1180-1180
Open Access | Times Cited: 20
The Application of Newcastle Disease Virus (NDV): Vaccine Vectors and Tumor Therapy
Huiming Yang, Jiaxin Tian, Ye Zhao, et al.
Viruses (2024) Vol. 16, Iss. 6, pp. 886-886
Open Access | Times Cited: 7
Development of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy
Fang Huang, Chuan-Jing Dai, You-Ni Zhang, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 23
Gene Therapy with Gene Delivery Systems and Therapeutic Strategies: A New Frontier in Cancer Treatment
Thippenahalli Narasimhaiah Ramakrishnaiah, Sowbhagya Ramachandregowda, Harsha Muktha, et al.
Journal of Drug Delivery Science and Technology (2025), pp. 106798-106798
Closed Access
Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses
Mahdie Jafari, Maryam Kadkhodazadeh, Mina Bahrololoumi Shapourabadi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 18
Viral Nanoparticles‐Mediated Delivery of Therapeutic Cargo
Saba Zanganeh, Mohammad Doroudian, Zohreh Nowzari, et al.
Advanced Therapeutics (2023) Vol. 6, Iss. 10
Closed Access | Times Cited: 10
Arenaviruses: Old viruses present new solutions for cancer therapy
Paweł Stachura, Olivia Stencel, Zhe Lü, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
miRNA-Mediated Mechanisms in the Generation of Effective and Safe Oncolytic Viruses
Мария Сергеевна Торопко, Sergey Chuvpilo, Alexander Karabelsky
Pharmaceutics (2024) Vol. 16, Iss. 8, pp. 986-986
Open Access | Times Cited: 3
Global Catastrophic Biological Risks in the Post-COVID-19 World: Time to Act Is Now
Manousos E. Kambouris
OMICS A Journal of Integrative Biology (2023) Vol. 27, Iss. 4, pp. 153-170
Closed Access | Times Cited: 6
Flaviviruses in AntiTumor Therapy
Alina S. Nazarenko, Mikhail F. Vorovitch, Yulia K. Biryukova, et al.
Viruses (2023) Vol. 15, Iss. 10, pp. 1973-1973
Open Access | Times Cited: 6
Encouraging probiotics for the prevention and treatment of immune-related adverse events in novel immunotherapies against malignant glioma
Sayuri Yoshikawa, Kurumi Taniguchi, Haruka Sawamura, et al.
Exploration of Targeted Anti-tumor Therapy (2022), pp. 817-827
Open Access | Times Cited: 8
Anti-cancer Virotherapy in Russia: Lessons from the Past, Current Challenges and Prospects for the Future
Nikolay B. Pestov, N. M. Kolyasnikova, Jeanne P. Sanchez-Pimentel, et al.
Current Pharmaceutical Biotechnology (2022) Vol. 24, Iss. 2, pp. 266-278
Closed Access | Times Cited: 7
Protein engineering for natural product biosynthesis: expanding diversity for therapeutic applications
Sarah Otun, Jordy Alexis Lerma-Escalera, Khayalethu Ntushelo, et al.
Journal of Bio-X Research (2023) Vol. 06, Iss. 02, pp. 49-60
Open Access | Times Cited: 3
Therapeutic potential of oncolytic viruses in the era of precision oncology.
Monchupa Kingsak, Thongpon Meethong, Jinnawat Jongkhumkrong, et al.
PubMed (2023) Vol. 4, Iss. 2, pp. 67-84
Closed Access | Times Cited: 3
CRISPR-to-Kill (C2K)–Employing the Bacterial Immune System to Kill Cancer Cells
Dawid Głów, Cécile L. Maire, Lea Isabell Schwarze, et al.
Cancers (2021) Vol. 13, Iss. 24, pp. 6306-6306
Open Access | Times Cited: 6
Development of an optimized, non‐stem cell line for intranasal delivery of therapeutic cargo to the central nervous system
Ali El‐Ayoubi, Arsen Arakelyan, Moritz Klawitter, et al.
Molecular Oncology (2023)
Open Access | Times Cited: 2
In vitro Characterization of Enhanced Human Immune Responses by GM-CSF Encoding HSV-1-Induced Melanoma Cells
Maike Delic, Veronika Boeswald, Katrin Goepfert, et al.
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 1291-1307
Open Access | Times Cited: 3
TheraVision: Engineering platform technology for the development of oncolytic viruses based on herpes simplex virus type 1
Christina Funk, Nadja Uhlig, Zsolt Ruzsics, et al.
Deleted Journal (2024) Vol. 32, Iss. 1, pp. 200784-200784
Open Access
The GCBR After COVID-19
Manousos E. Kambouris
Advanced sciences and technologies for security applications (2024), pp. 143-186
Closed Access
YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells
Anna Josefine von Ofen, Uwe Thiel, Jennifer Eck, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Neutrophils in oncolytic virus immunotherapy
Danya Zhou, Chenglin Zhang, Jingyi Sun, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Establishing a New Platform to Investigate the Efficacy of Oncolytic Virotherapy in a Human Ex Vivo Peritoneal Carcinomatosis Model
J. Koch, Julia Beil, Susanne Berchtold, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 363-363
Open Access | Times Cited: 1
Gene Therapy “Made in Germany”: A Historical Perspective, Analysis of the Status Quo, and Recommendations for Action by the German Society for Gene Therapy
Hildegard Büning, Boris Fehse, Zoltán Ivics, et al.
Human Gene Therapy (2021) Vol. 32, Iss. 19-20, pp. 987-996
Closed Access | Times Cited: 3
Serendipitous synergism – an exceptional response to treatment with pembrolizumab in the course of a natural immunovirotherapy: a case report and review of the literature
Lara M. Khoury, Kimberly M. Burcher, Ronald T. Ng, et al.
Therapeutic Advances in Medical Oncology (2022) Vol. 14
Open Access | Times Cited: 2
Improved Production Strategies for Oncolytic Measles Viruses as a Therapeutic Cancer Treatment
Dustin Eckhardt, Sascha Bossow, Jan-Philip Klee, et al.
Springer eBooks (2023), pp. 375-405
Closed Access
Page 1 - Next Page

Scroll to top